Divi's Laboratories Limited — Investor Meet, 07-02-2025: Analysts/Institutional Investor Meet/Con. Call Updates

**Financial Performance:** Divi's Laboratories reported a total income of ₹2,401 crores for the quarter, a 25% increase from ₹1,915 crores year-over-year. Profit before tax rose to ₹726 crores, up from ₹489 crores, while profit after tax reached ₹589 crores compared to ₹358 crores in the previous year. Over the nine-month period, total income increased to ₹7,041 crores from ₹5,804 crores, with profit before tax at ₹2,052 crores, surging from ₹1,450 crores. The current material consumption stood at 40% of sales revenue.

**Future Outlook and Growth Drivers:** Management highlighted steady growth in revenue driven primarily by the custom synthesis and generic segments. Anticipated patent expirations may provide additional traction for generics. The company's Nutraceutical division demonstrated market share growth, alongside ongoing investments in technology and capacity expansions.

**Order Book and Operational Updates:** The Kakinada facility’s Phase I has commenced commercial operations, strengthening backward integration and enhancing production capabilities. The management remains optimistic about future projects developed in collaboration with customers, particularly in contrast media and GLP-1 peptides.

**Analyst Q&A Insights:** Analysts probed factors influencing revenue projections and margins. Management indicated expectations of gradual market stabilization and potential regulatory approvals affecting product timelines, particularly for new projects.

**Market or Regulatory Updates:** The logistics landscape has shown signs of stabilization after easing supply chain pressures, with future freight rate normalizations anticipated amid geopolitical recovery.

**Strategic Focus Areas:** Key strategic themes included increased customer engagement, a focus on sustainability, and continuous investments in technology. The company is committed to mitigating operational risks while enhancing cost efficiencies.

**Investor Insight:** The robust financial health, coupled with strong growth potential from strategic projects and an expanding product portfolio, positions Divi's Laboratories favorably for future performance, suggesting a ‘buy’ stance for retail investors.